|
|
|
|
|
|
Sponsored by: |
GlaxoSmithKline |
Information provided by: | GlaxoSmithKline |
ClinicalTrials.gov Identifier: | NCT00553657 |
The purpose of this study is to determine if standardizing fluid intake in a clinic setting will reduce variability of individual voiding parameters and potentially serve as a way to limit patient exposure in the initial assessment of efficacy of compounds being developed for Overactive Bladder.
Condition | Intervention | Phase |
Overactive Bladder |
Drug: DETROL LA (drug) |
Phase I |
ChemIDplus related topics: | Tolterodine Tolterodine tartrate |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Double-Blind, Active Control, Parallel Assignment, Pharmacodynamics Study |
Official Title: | A Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Effect of Standardization of Fluid Intake on the Variability of Measured Voiding Parameters in Female Patients With Idiopathic Overactive Bladder |
Enrollment: | 55 |
Study Start Date: | August 2007 |
Study Completion Date: | January 2008 |
Primary Completion Date: | January 2008 (Final data collection date for primary outcome measure) |
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Female |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Australia, New South Wales | |||||
GSK Clinical Trials Call Center | |||||
Randwick, New South Wales, Australia, 2031 |
GlaxoSmithKline |
Study Director: | GSK Clinical Trials, MD | GlaxoSmithKline |
Study ID Numbers: | BKB105190 |
First Received: | November 2, 2007 |
Last Updated: | June 12, 2008 |
ClinicalTrials.gov Identifier: | NCT00553657 |
Health Authority: | Australia: Department of Health and Ageing Therapeutic Goods Administration |
|
|
|